

Birmingham,AL F: 205-271-9971

Huntsville, AL F: 256-417-6408

Knoxville, TN F: 865-934-0249

Nashville, TN F: 615-645-4791

Chantilly, VA F: 703-935-2061

☐ Tried & Failed Therapies

lm

mune Globulin Referral Form		Last 4 SSN#:
Date: Patient Name:	Phone:	Male Female
Patient Address:	Insurance Name & ID#:	
Referral Contact Name & Number:	Insurance Name & ID#:	

	atient Address:		Insurance Name & ID#:	
Re	eferral Contact Name & Number:		Insurance Name & ID#:	
Sel	lect Applicable Diagnosis and Include Recent	Visit I	Notes and Diagnosis Specific Supporting Clinical Noted:	
Im		urrent8 s, one ost se ent vks / or r cells uired)	Neurology (ICD Codes) □ Chronic Inflammatory Demyelinating Polyneuropathy (G61.81) Document dx, progressive neurological symptoms, Electromyogram/Nerve Conduction (EMG/NCS), CSF (if available) □ Multifocal Motor Neuropathy (G61.82) Documented dx & hx, Electromyogram/Nerve Conduction (EMG/NCS) □ Guillain-Barre Syndrome (G61.0) Documented dx & hx of illness □ Myasthenia Gravis (G70.0/G70.01) Documented dx & worsening symptoms, + acetylcholine receptor (AChR) abs □ Multiple Sclerosis (G35) Documented dx of relapsing-remitting MS and previous treatments, diagnostic testing (ex. Neuro exam, MRI, +CSF study) Transplant (ICD Codes) □ Bone Marrow Transplant/Stem Cell Transplant Recipients (Z94.81/Z94.84) Documented hx infection, date of Tx, pre-treatment low to IgG level □ Solid Organ Transplant (Z94)Documented dx & hx including indication for IVIG: □ Pre-transplant: high panel reactive antibody to human leukocyte antigens (HLA) (T86.91) □ Post-transplant: Graft vs Host Disease (D89.810) □ Post-transplant: recipients at risk for CMV (T86.0) □ Post-transplant: treatment for antibody mediated rejection (T86.11) Other (ICD Codes) □ B-cell Chronic Lymphocytic Leukemia (C91.11) Documented hx	otal
	enzymes, muscle biopsy, skin biopsy) Stiff Persons Syndrome (G25.8) Documented dx and hx or line treatments, anti-GAD antibody testing	of first	recurrent infections and date of Tx, pre-treatment low IgG level	
	Detailed Written Orders:			
	Height: ☐ Inches ☐ cm Weight: ☐ Ibs ☐ kg	Dos	e:	
	Allergies:		juency: Duration:	
	☐ IVIG (pharmacist to brand) ☐ SCIG (pharmacist to brand)			
	□ Gamunex-C (J1561) □ Hizentra (J1559) □ Gammagard (J1569) □ Xembify (J1558) □ Privigen (J1459) □ HyQvia(J1575) □ Panzyga (J1599) □ Cutaquig(J3590) □(other) □(other)	Prem H Othe	parmacist to dose redication: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: pr: parmacy OK to Substitute Brand when Insurance Dictates	
[]	□Gammagard (J1569) □Xembify (J1558) □Privigen (J1459) □HyQvia(J1575) □Panzyga (J1599) □Cutaquig(J3590)	Prem H Othe	edication: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: er: narmacy OK to Substitute Brand when Insurance Dictates illary orders will include:	
F N	□Gammagard (J1569) □Xembify (J1558) □Privigen (J1459) □HyQvia(J1575) □Panzyga (J1599) □Cutaquig(J3590) □(other) □(other)	Prem H Othe Pr Anc Skille NaC Hepa	ydration: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: er: narmacy OK to Substitute Brand when Insurance Dictates	
[□ Gammagard (J1569) □ Xembify (J1558) □ Privigen (J1459) □ HyQvia(J1575) □ Panzyga (J1599) □ Cutaquig(J3590) □ □ □ (other) □ □ (other) □ IgA level: □ N/A: □ □ No: □ Previous Brands: □ Next Dose Due: □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	Prem H Othe Pr Anc Skille NaC Hep: All ir	ydration: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: pr: harmacy OK to Substitute Brand when Insurance Dictates illary orders will include: ed Nursing Visits to administer (IVIG) and/or teach (SCIG) Infusions I 0.9% 5-10ml IV before and after infusion for peripheral access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN infusion supplies necessary to administer the medication ohylaxis Kit	
FF L By By	□ Gammagard (J1569) □ Xembify (J1558) □ Privigen (J1459) □ HyQvia(J1575) □ Panzyga (J1599) □ Cutaquig(J3590) □ □ □ (other) □ □ (other) □ □ N/A: □ □ No: □ Previous Brands: □ Next Dose Due: □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □	Prem H Othe Prem Anc Skille NaC Hepa All irr Anap	ydration: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: pr: narmacy OK to Substitute Brand when Insurance Dictates illary orders will include: ed Nursing Visits to administer (IVIG) and/or teach (SCIG) Infusions I 0.9% 5-10ml IV before and after infusion for peripheral access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN infusion supplies necessary to administer the medication ohylaxis Kit SQ K0552 Pump, A4221 Cath Supplies, A4222 Pump Supplies ary. Prescriber's Signature (SIGN BELOW) r authorization agent with medical & pharmacy insurance providers. Referral Checklist: Patient Demographics Copy Insurance Card	
[Gammagard (J1569)	Prem H Othe Prem Anc Skille NaC Hep: All irr Anap upplies	ydration: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: pr: price pri	
C	Gammagard (J1569)	Prem H Othe Prem Anc Skille NaC Hepa All irr Anap	ydration: Diphenhydramine 25mg PO Acetaminophen 650mg PO ydration: pr: harmacy OK to Substitute Brand when Insurance Dictates illary orders will include: ed Nursing Visits to administer (IVIG) and/or teach (SCIG) Infusions 0.9% 5-10ml IV before and after infusion for peripheral access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after infusion for Port IV access and PRN arin 100 units/ml 3-5ml IV after in	